The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges

Published:2020-09 Issue: Volume:213 Page:107579
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Tundo G.R.,Sbardella D.,Santoro A.M.,Coletta A.,Oddone F.,Grasso G.,Milardi D.,Lacal P.M.,Marini S.,Purrello R.,Graziani G.,Coletta M.

Funder

Italian Association for Cancer Research

Italian Ministry of Health

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference1141 articles.

1. p21 in cancer: intricate networks and multiple activities;Abbas;Nature Reviews. Cancer,2009

2. The proteasome: structure, function, and role in the cell;Adams;Cancer Treatment Reviews,2003

3. The development of proteasome inhibitors as anticancer drugs;Adams;Cancer Cell,2004

4. The proteasome: a suitable antineoplastic target;Adams;Nature Reviews. Cancer,2004

5. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids;Adams;Bioorganic & Medicinal Chemistry Letters,1998

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CaMKII suppresses proteotoxicity by phosphorylating BAG3 in response to proteasomal dysfunction;EMBO Reports;2024-09-11

2. Design, synthesis, and biological evaluation of novel 1-amido-2-one-4-thio-deoxypyranose as potential antitumor agents for multiple myeloma;Bioorganic & Medicinal Chemistry;2024-09

3. Current Strategies and Future Directions in Multiple Myeloma: Disease Overview and Pathophysiology, Conventional Treatments and Emerging Therapies, Challenges and Innovations in Management;European Journal of Medical and Health Research;2024-09-01

4. Targeting Microglial Immunoproteasome: A Novel Approach in Neuroinflammatory-Related Disorders;ACS Chemical Neuroscience;2024-07-06

5. Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma;Cancer Medicine;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3